|
| 37301715 | Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. | | 2023 |
| 37219686 | Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. | | 2023 |
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 30691991 | Revolutionizing treatment of advanced melanoma with immunotherapy. | Surgical Oncology | 2022 |
| 35902131 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. | J Immunother Cancer | 2022 |
| 35678233 | Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. | Melanoma Research | 2022 |
| 35665462 | Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era? | J Neurooncol | 2022 |
| 36450385 | Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. | J Immunother Cancer | 2022 |
| 36619972 | Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. | iScience | 2022 |
| 36532509 | A multidisciplinary management algorithm for brain metastases. | Neurooncol Adv | 2022 |
| 34641962 | Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma. | Genome Medicine | 2021 |
| 31977647 | Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis. | Journal of Clinical Rheumatology | 2021 |
| 33741813 | Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. | Melanoma Research | 2021 |
| 33880555 | Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). | Neuro Oncol | 2021 |
| 33979178 | Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. | J Clin Oncol | 2021 |
| 33208341 | Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. | Clin Cancer Res | 2021 |
| 33084375 | First-line immunotherapy versus targeted therapy in patients with -mutant advanced melanoma: a real-world analysis. | Future Oncology | 2021 |
| 33234846 | Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). | Melanoma Res | 2021 |
| 32666149 | Current concepts and approaches to merkel cell carcinoma. | Archives of Dermatological Research | 2021 |
| 33414132 | The State of Melanoma: Emergent Challenges and Opportunities. | Clin Cancer Res | 2021 |
| 34909742 | Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma. | | 2021 |
| 34774225 | Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. | Lancet Oncol | 2021 |
| 30943789 | Ipsilateral metastatic choroidal melanoma responds to systemic immunotherapy. | Eur J Ophthalmol | 2020 |
| 31699709 | Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. | Cancer Immunol Res | 2020 |
| 32413929 | Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer. | Facial Plastic Surgery | 2020 |
| 31732523 | Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma. | Clin Cancer Res | 2020 |
| 32303614 | Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. | Journal for ImmunoTherapy of Cancer | 2020 |
| 31662331 | TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. | Clin Cancer Res | 2020 |
| 31977051 | Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. | Journal of the National Cancer Institute | 2020 |
| 32441371 | Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy. | Journal of Surgical Oncology | 2020 |
| 32087194 | TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. | | 2020 |
| 31653641 | Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. | Clin Cancer Res | 2020 |
| 32550269 | Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma. | npj Precision Oncology | 2020 |
| 32804707 | Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma. | Melanoma Research | 2020 |
| 32894847 | Management of Melanoma during Pregnancy: A Case Series of 11 Women Treated at NYU Langone Health. | Oncology | 2020 |
| 32554615 | Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. | Journal for ImmunoTherapy of Cancer | 2020 |
| 35121932 | Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. | Nat Cancer | 2020 |
| 31037288 | HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. | J Natl Cancer Inst | 2020 |
| 31308438 | Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). | Scientific Reports | 2019 |
| 31597568 | Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. | Genome Medicine | 2019 |
| 29912415 | Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. | Journal of the National Cancer Institute | 2019 |
| 30334646 | Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. | Future Oncology | 2019 |
| 30863922 | Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. | Cancer Immunol Immunother | 2019 |
| 31129314 | Gamma Knife Radiosurgery and Immunotherapy as Primary Treatment for a Malignant Tumor of the Cranial Base Beginning as Lentigo Maligna: A Case Report. | Practical Radiation Oncology | 2019 |
| 31026246 | Impact of initial stage on metastatic melanoma survival. | Melanoma Research | 2019 |
| 30690710 | A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. | Cancer | 2019 |
| 30909967 | Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series. | J Immunother Cancer | 2019 |
| 31218477 | Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. | Breast Cancer Research and Treatment | 2019 |
| 30903140 | A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. | Ann Oncol | 2019 |
| 31426863 | The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. | Journal for ImmunoTherapy of Cancer | 2019 |